(Q44534080)

3 December 2017

title

Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours (English)

1 reference

3 December 2017

Neutel J

1

1 reference

3 December 2017

Weber M

2

1 reference

3 December 2017

Pool J

3

1 reference

3 December 2017

Smith D

4

1 reference

3 December 2017

Fitzsimmons S

5

1 reference

3 December 2017

Chiang YT

6

1 reference

3 December 2017

Gatlin M

7

1 reference

3 December 2017

publication date

1 May 1997

1 reference

3 December 2017

published in

Clinical Therapeutics

1 reference

3 December 2017

volume

19

1 reference

3 December 2017

issue

3

1 reference

3 December 2017

page(s)

447-58; discussion 367-8

1 reference

Role of blood pressure in cardiovascular morbidity and mortality

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Blood pressure, stroke, and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Morning increase in onset of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Circadian variation of transient myocardial ischemia in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

Duration of action of angiotensin converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980129-4

7 January 2021

10.1016/S0149-2918(97)80129-4

Identifiers

DOI

1 reference

3 December 2017

1 reference